Clinical Trials
14 trialsNCT05474690 2024-02-26
A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer
Henan Cancer Hospital
Phase 3 Withdrawn
NCT02067416 2023-02-02
PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer
The Methodist Hospital Research Institute
Phase 2 Withdrawn
NCT02651610 2017-07-11
Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer
Peregrine Pharmaceuticals
Phase 2/3 Withdrawn
NCT00937417 2017-04-24
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
SWOG Cancer Research Network
Phase 1 Withdrawn
NCT00774241 2016-11-02
PRIMADOS Study:A Study of Avastin (Bevacizumab) Plus Docetaxel for First Line Treatment of Patients With Metastatic Breast Cancer
Hoffmann-La Roche
Phase 4 Withdrawn
NCT00964704 2016-11-02
A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer
Hoffmann-La Roche
Phase 2 Withdrawn
NCT00041171 2016-07-12
Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
Alliance for Clinical Trials in Oncology
Phase 3 Withdrawn
NCT00471159 2015-05-04
A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.
Pfizer
Phase 2 Withdrawn
NCT00678626 2015-05-04
Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer
Pfizer
Phase 2 Withdrawn
NCT00074139 2014-03-05
Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer
Case Comprehensive Cancer Center
Phase 1 Withdrawn
NCT01137994 2013-03-13
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
GlaxoSmithKline
Phase 2 Withdrawn
NCT00434031 2012-07-30
CETRA
National Cancer Institute, Naples
Phase 2 Withdrawn
NCT01229605 2011-12-12
Cyclophosphamide and Docetaxel Every 3 Weeks as Neoadjuvant Therapy in Locally Advanced Breast Cancer
Tufts Medical Center
Phase 2 Withdrawn
NCT00006261 2010-06-10
Allogeneic Transplantation Using Mini-Conditioning for Treatment of Stage IV Breast Cancer
Case Comprehensive Cancer Center
Phase 2 Withdrawn